Immuron Limited · ASX:IMC
Immuron — AusBiotech Invest 2025 Conference
17 slides from Immuron's conference presentation, Oct 21, 2025
Slide 1: Immuron CEO presentation to AusBiotech Invest 2025 conference
Immuron CEO, Steven Lydeamore presentation to AusBiotech Invest 2025 conference Melbourne, Australia, October 21, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the AusBiotech Invest conference on Tuesday 21st O
Slide 2: IMM-124E (Travelan) and IMM-529 background
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: IBS market, references and forward-looking statements
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: AusBiotech Invest 2025
Crown Towers INVEST in ieLBOURNE HEALTH 21Oct 2025 VW AusBiotech Invest 2025 IMMUFeN @AusBiotechinvest #AusBiotechInvest2025 #ABI25 -
Slide 5: For personal use only
WZ AusBiotech INVEST in Crown Towers Invest 2025 IMMULON We = E \ — Pa ee x 3 a Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases. lImmuron has three co
Slide 6: For personal use only
Prof. Ravi Savarirayan Director Former CEO of Polynovo (ASX:PNV). 2021): market cap. $30M to peak of $2B Clinical geneticist; Professor and Research IMMUFeN Steven Lydeamore Chief Executive Officer Group Leader (Skeletal Biology and Disease) at the Murdoch Children's Research Institute Flavio Palumb
Slide 7: FY25 Financial Summary
FY25 Financial Summary For personal use only Global Sales Australian Sales North American Revenue Revenue Sales Revenue $7.3m $5.3m $2.0m Up 49% Up 40% Up 76% EBITDA (ex- Cash + Term Gross Profit R&D)1 Deposit Margin $(3.1)m $5.9m (excludes 65.4% $2.1m A$2.8m raised from improvement the US placement
Slide 8: Travelan continued strong sales growth
Travelan® continued strong sales growth For personal use only Global Global Year to Date Net Sales ($AUD) + FY2025 AUD$7.3 million up 49% on prior year $8,000,000 + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 $6,000,000 $4,000,000 $2,000,000 $- Australia Jul - Sep Oct - Dec Jan - Mar Apr - Jun + F
Slide 9: Technology Platform
Technology Platform For personal use only Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 10: Pipeline and Key Milestones
Pipeline and Key Milestones For personal use only Peak U.S. Collaborator or Funding Anticipated Dates Indication Compound Preclinical Phase 1 Phase 2 Phase 3 Registration Current Status sales Source 2H 2025 2026 2027 2028 2029 Uniformed 100% of 851 Traveller's Diarrhoea Travelan® US$ 102 m Services
Slide 11: Traveller's Diarrhoea
For personal use only Diarrhoea Traveller’s
Slide 12: Travelan
For personal use only Travelan® .
Slide 13: Clostridioides Difficile Infection
Clostridioides Difficile Infection For personal use only
Slide 14: IMM-529
For personal use only IMM-529
Slide 15: Commercial Opportunity
Commercial Opportunity For personal use only › Immuron’s development of IMM-124E (hyperimmune bovine › Infectious disease experts reacted favorably to the IMM-529 MOA, colostrum) as a prescription medication has the potential to and its unique ability to target three elements of the rCDI infection a
Slide 16: Global Biotech with Real-World Impact
Global Biotech with Real-World Impact lImmuron is one of the few ASX-listed biopharma companies with both commercialised products anda USS. dual listing (NASDAQ: IMRN). With a global footprint spanning Australia, the U.S., and Canada, the company is executing on a cross-border growth strategy suppor
Slide 17: For personal use only
4EALTH 1Oct 2025 ~ IMMUreoNn @AusBiotechinvest #AusBiotechInvest2025 #ABI25